# A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

> **NCT05093322** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hutchmed** · enrollment: 13 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma
- Osteosarcoma
- Ewing Sarcoma
- Rhabdomyosarcoma
- Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

## Interventions

- **DRUG:** Surufatinib in combination with Gemcitabine

## Key facts

- **NCT ID:** NCT05093322
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-04-25
- **Final completion:** 2023-04-25
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093322, "A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05093322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*